Abstract
Despite advances in multidisciplinary approaches, the prognosis for most patients with malignant gliomas is poor. Malignant gliomas are highly vascularized tumors with elevated expression of vascular endothelial growth factor (VEGF), an important mediator of angiogenesis. Recent studies of bevacizumab, an anti-VEGF monoclonal antibody, alone or associated with chemotherapy, have demonstrated high response rates and prolongation of median and 6-month progression-free survival. Clinical evaluation of several multitarget small molecule tyrosine kinase inhibitors is ongoing. Other promising antiangiogenic compounds are cilengitide and continuous temozolomide. Toxicity is acceptable. Open issues are represented by patterns of tumor progression, resistance mechanisms and biomarkers.
Keywords: Bevacizumab, cilengitide, glioblastoma, resistance, temozolomide, toxicity, VEGF, basement membrane, extracellular matrix, hepatocyte growth factor/scatter factor, hypoxia inducible factor-1a, overall survival, phosphatase and tensin homolog, vascular endotelial growth factor, progression free surivival
Current Cancer Drug Targets
Title: Anti-Angiogenic Approaches to Malignant Gliomas
Volume: 12 Issue: 3
Author(s): R. Soffietti, E. Trevisan, L. Bertero, C. Bosa and R. Ruda
Affiliation:
Keywords: Bevacizumab, cilengitide, glioblastoma, resistance, temozolomide, toxicity, VEGF, basement membrane, extracellular matrix, hepatocyte growth factor/scatter factor, hypoxia inducible factor-1a, overall survival, phosphatase and tensin homolog, vascular endotelial growth factor, progression free surivival
Abstract: Despite advances in multidisciplinary approaches, the prognosis for most patients with malignant gliomas is poor. Malignant gliomas are highly vascularized tumors with elevated expression of vascular endothelial growth factor (VEGF), an important mediator of angiogenesis. Recent studies of bevacizumab, an anti-VEGF monoclonal antibody, alone or associated with chemotherapy, have demonstrated high response rates and prolongation of median and 6-month progression-free survival. Clinical evaluation of several multitarget small molecule tyrosine kinase inhibitors is ongoing. Other promising antiangiogenic compounds are cilengitide and continuous temozolomide. Toxicity is acceptable. Open issues are represented by patterns of tumor progression, resistance mechanisms and biomarkers.
Export Options
About this article
Cite this article as:
Soffietti R., Trevisan E., Bertero L., Bosa C. and Ruda R., Anti-Angiogenic Approaches to Malignant Gliomas, Current Cancer Drug Targets 2012; 12 (3) . https://dx.doi.org/10.2174/156800912799277584
DOI https://dx.doi.org/10.2174/156800912799277584 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry Boronated Compounds for Imaging Guided BNCT Applications
Anti-Cancer Agents in Medicinal Chemistry Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics Sphingolipid Modulation: A Strategy for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology?
Current Neuropharmacology Toxicological Profile of Therapeutic Nanodelivery Systems
Current Drug Metabolism Endoradiotherapy with Peptides - Status and Future Development
Current Medicinal Chemistry Natural Antibodies: Protecting Role of IgM in Glioblastoma and Brain Tumours
Current Pharmaceutical Design Drug Repositioning for Treatment of Movement Disorders: From Serendipity to Rational Discovery Strategies
Current Topics in Medicinal Chemistry The Role of TNFSF15 in the Modulation of Neovascularization and Inflammation
Current Hypertension Reviews Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology Circumventing Melanoma Chemoresistance by Targeting DNA Repair
Current Medicinal Chemistry The Plasminogen Activation System Promotes Neurorepair in the Ischemic Brain
Current Drug Targets Current Issues in the Utility of Blood Oxygen Level Dependent MRI for the Assessment of Modulations in Tumor Oxygenation
Current Medical Imaging Cruciferous Plants: Phytochemical Toxicity Versus Cancer Chemoprotection
Mini-Reviews in Medicinal Chemistry Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Targeting Role of Glioma Stem Cells for Glioblastoma Multiforme
Current Medicinal Chemistry